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myotrophic lateral sclerosis (ALS) is a progres-
sive neurodegenerative disease characterized
by a selective degeneration of motor neurons,
atrophy, and paralysis of skeletal muscle. Although a sig-
niﬁcant proportion of familial ALS results from a toxic
gain of function associated with dominant SOD1 muta-
tions, the etiology of the disease and its speciﬁc cellular
origins have remained difﬁcult to deﬁne. Here, we show
that muscle-restricted expression of a localized insulin-
like growth factor (Igf) -1 isoform maintained muscle in-
tegrity and enhanced satellite cell activity in SOD1
 
G93A
A
 
transgenic mice, inducing calcineurin-mediated regener-
ative pathways. Muscle-speciﬁc expression of local Igf-1
(mIgf-1) isoform also stabilized neuromuscular junctions,
reduced inﬂammation in the spinal cord, and enhanced
motor neuronal survival in SOD1
 
G93A
 
 mice, delaying the
onset and progression of the disease. These studies estab-
lish skeletal muscle as a primary target for the dominant
action of inherited SOD1 mutation and suggest that muscle
ﬁbers provide appropriate factors, such as mIgf-1, for
neuron survival.
 
Introduction
 
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular
disorder involving the degeneration of motor neurons accom-
panied by skeletal muscle atrophy and paralysis. Transgenic
mice ubiquitously overexpressing human SOD1 mutants develop
motor neuron disease resembling ALS (Gurney et al., 1994)
and provide useful model to test potential therapeutic strategies
in disease treatment.
Notably, restriction of SOD1 mutant expression selectively
to post-natal motor neurons failed to produce detectable sign of
pathology or motor-neuron disease (Lino et al., 2002), suggest-
ing that other cell types may be involved in ALS-associated
neurodegeneration.
Indeed, analysis of chimeras generated between wild-
type and SOD1 mutant mouse embryonic cells revealed that
wild-type non neuronal cells in adult chimeric animals extended
the survival of SOD1 mutant motor neurons, suggesting that
the neurodegenerative action of mutant SOD1 may operate
through a dominant paracrine activity emanating from non-
neuronal cells (Clement et al., 2003).
Skeletal muscle is an untested component in the motor
neurodegenerative effects of SOD1 mutations. Adult muscle
fibers are a source of signals that influence neuron survi-
val, axonal growth, and maintenance of synaptic connections
(Funakoshi et al., 1995). Among these, insulin-like growth
factor 1 (Igf-1) has been implicated in anabolism of muscle and
nerve tissues, inducing muscle hypertrophy and promoting
neuronal survival (Musarò and Rosenthal, 2002).
In a recent study, injection of SOD1 mutant mouse muscle
with an adeno-associated virus carrying an Igf-1 gene pro-
longed life and delayed disease progression (Kaspar et al.,
2003). Retrograde transport of the AAV–Igf-1 vector to the
spinal cord was reported necessary to achieve therapeutic
effects (Kaspar et al., 2003). However, it is not clear from that
study which Igf-1 isoform was used, or whether the effects of
Igf-1 expressed in motor neurons were cell autonomous.
Two major isoforms of Igf-1, originating from alternative
splicing, have been described, differing in structure and func-
tions (Musarò and Rosenthal, 2002). These isoforms are referred
as circulating (class 2) and local (class 1) Igf-1. Igf-1 class 2
transcripts predominate in the liver, are highly growth hormone
(GH) responsive and as such are major endocrine effectors of
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GH. By contrast, class 1 transcripts are widely expressed in all
tissues, but remain preferentially confined to the tissue of ex-
pression. The contribution to more localized accumulation of
Igf-1 class 1 seems due to the combination of exon 1, Ea pep-
tide, and a lower binding affinity to Igf binding proteins, com-
pared with circulating class 2 isoform (Fig. S1, available at http:
//www.jcb.org/cgi/content/full/jcb.200407021/DC1).
To assess the effects of supplemental Igf-1 directly on atro-
phic SOD1 skeletal muscle, we exploited a transgenic mouse ex-
pressing a full-length precursor of the local isoform of Igf-1
(mIgf-1) that is normally induced transiently in response to mus-
cle damage, but does not enter the circulation (Musarò et al.,
2001; Musarò and Rosenthal, 2002). Muscle restricted mIgf-1
transgene (MLC/mIgf-1) exerts its effects in an autocrine/para-
crine manner, circumventing the adverse side effects of systemic
Igf-1 administration. Expression of the MLC/mIgf-1, delivered
either as an inherited transgene or somatically on an AAV vec-
tor, induces muscle hypertrophy and strength, and preserves re-
generative capacity in senescent and dystrophic mice (Barton-
Davis et al., 1998; Musarò et al., 2001; Barton et al., 2002)
through enhanced stem cell recruitment (Musarò et al., 2004).
In the present study, we establish skeletal muscle as a pri-
mary target in inherited forms of ALS by showing that local-
ized expression of the coinherited MLC/mIgf-1 transgene
exclusively in the skeletal muscle of SOD1
 
G93A
 
 mice counter-
acted the symptoms of ALS, induced satellite cell activity, sta-
bilized neuromuscular junctions, and led to a reduction in
astrocytosis in the SOD1
 
G93A
 
 spinal cord. These observations
suggest novel approaches to the attenuation of motor neuronal
degradation and underscore the importance of Igf-1 isoform
selection when designing therapeutic strategies for ALS.
 
Results and discussion
 
Muscle-specific mIgf-1 delays the 
progression of the disease and prolongs 
the life span of SOD1
 
G93A
 
 mice
 
To evaluate the effects of mIgf-1 on the SOD1
 
G93A
 
 neurodegen-
erative phenotype, we compared double transgenic SOD1
 
G93A
 
and MLC/mIgf-1 transgenic mice to their SOD1
 
G93A
 
 litter-
mates. The SOD
 
G93A
 
 and SOD1
 
G93A
 
 
 
 
 
 MLC/mIgf-1 (SOD1
 
G93A
 
/
mIgf-1) transgenic mice were selected for same expression
level of the human transgenic protein (Fig. 1 a). Notably, the
mIgf-1 transgene was selectively expressed in skeletal muscle
of both MLC/mIgf-1 and SOD1
 
G93A
 
/mIgf-1 mice (Fig. 1 b,
lanes 2 and 4), whereas it was not expressed in the brain and
spinal cord (Fig. 1 b, lanes 5–8), or in skeletal muscle of wild-
type and SOD
 
G93A
 
 mice (Fig. 1 b, lanes 1 and 3).
Figure 1.  mIgf-1 expression delays the progression of the disease and enhances the survival of SOD1
G93A mutant mice. (a) Western blot analysis of
human SOD transgenic protein in wild-type (lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A (lane 3) and SOD1
G93A/mIgf-1 (lane 4) transgenic muscle. (b) Northern
blot analysis for mIgf-1 transgene expression in skeletal muscle of wild-type (wt; lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A (lane 3) and SOD1
G93A/mIgf-1
(lane 4) transgenic mice; in brain and spinal cord of MLC/mIgf-1 (lanes 5 and 7) and SOD1
G93A/mIgf-1 (lanes 6 and 8) mice. (c) Age of onset of disease
symptoms; average onset: SOD1
G93A (n   30)   111   1.8; SOD1
G93A/mIgf-1 (n   30)   120.8   1.0 (d) analysis of the progression of the disease;
average of disease duration: SOD1
G93A (n   30)  12   0.6; SOD1
G93A/mIgf-1 (n   30)   32   0.8 (e) survival analysis; average survival: SOD1
G93A
(n   30)   123   1.4; SOD1
G93A/mIgf-1 (n   30)   152.8   1.4. 
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At 111 
 
 
 
 1.8 d old, disease onset was observed in the
mutant SOD1
 
G93A
 
 transgenic mice (
 
n
 
 
 
 
 
 30; Fig. 1 c). Notably,
the SOD1
 
G93A
 
 mice died within 10 d 
 
 
 
 0.6 of clinical disease
onset (Fig. 1 d), with a maximal life span of 145 d (Fig. 1 e).
By contrast, localized expression of mIgf-1 delayed the onset
(Fig. 1 c) and in particular the progression (Fig. 1 d) of disease,
increasing the survival of SOD1
 
G93A
 
/mIgf-1 mice (
 
n
 
 
 
 
 
 30) by
 
 
 
30 d to a maximal life span of 175 d (Fig. 1 e). Differences
between SOD1
 
G93A
 
 and SOD1
 
G93A
 
/mIgf-1 were significantly rel-
evant for onset (
 
 
 
2
LR
 
 
 
 
 
 18.7, P 
 
 
 
 0.0001), progression (
 
 
 
2
LR
 
 
 
 
 
67.0, P 
 
  
 
0.0001), and survival (
 
 
 
2
LR
 
 
 
 
 
 63.2, P 
 
 
 
 0.0001).
 
mIgf-1 expression attenuates muscle 
atrophy, increasing satellite cell 
activation in SOD1
 
G93A
 
 mice
 
SOD1
 
G93A
 
 (
 
n
 
 
 
 
 
 7) and SOD1
 
G93A
 
/mIgf-1 (
 
n
 
 
 
 
 
 7) transgenic
mice were analyzed at different stages of disease. At 123 d,
motor neuronal degeneration of SOD1
 
G93A
 
 mice was accompa-
nied by severe muscle atrophy (Fig. 2 a, E), and complete mus-
cle paralysis (hereafter this stage is indicated as paralysis
stage). In contrast, at the same age, SOD1
 
G93A
 
/mIgf-1 trans-
genic mice did not show evident signs of muscle disease, but
only difficulty in extending the limbs when suspended (hereaf-
ter this stage is indicated as symptom onset). Moreover, muscle
atrophy was substantially attenuated in SOD1
 
G93A
 
/mIgf-1 off-
spring even after onset of denervation and paralysis stage (153 d
old; Fig. 2 a, F; Fig. 2 b). In addition, markers of satellite cell
activity, such as Pax-7 and desmin, were increased to varying
extents in affected SOD
 
G93A
 
 mice (Fig. 2 c), whereas hallmarks
of satellite cell activity and fiber maturation, including central-
ized nuclei (Fig. 2 a, yellow arrows), Pax-7 isoforms, desmin,
myogenin, and neonatal myosin heavy chain (MyHC) expres-
sion were present exclusively in the SOD1
 
G93A
 
/mIgf-1 muscles
at all stages of disease, including at paralysis stage (Fig. 2 c and
not depicted), Thus, satellite cell activation is likely to contrib-
ute to the maintenance of muscle phenotype induced by mIgf-1
expression (Barton-Davis et al., 1999).
Motor neurons are known to regulate the properties of the
myofibers they innervate by selective activation of fiber spe-
cific gene expression. Immunohistochemical analysis (Fig. 2 d)
revealed that fiber type composition was altered in SOD1
 
G93A
 
soleus muscle even before overt disease (80 d), with a shift to-
ward a fast fiber type. In contrast, normal heterogeneity of
muscle fibers was maintained for a more extended period in
SOD1
 
G93A
 
/mIgf-1 mice, which showed shifts in fiber composi-
tion only at later stage of disease (Fig. 2 d, 138 d). By paralysis
stage (153 d) there was not significant difference in fiber type
composition between SOD1
 
G93A
 
 and SOD1
 
G93A
 
/mIgf-1 mice
Figure 2.  mIgf-1 expression attenuates
muscle wasting and promotes regenerative
pathways in SOD1
G93A mice. (a) Histological
analysis of wt, MLC/mIgf-1, SOD1
G93A and
SOD1
G93A/mIgf-1 muscle at different age and
stage of disease. Bar, 20  m (b) Analysis of
fiber size differences in the quadriceps under-
scores the relative attenuation of muscle atrophy
in SOD1
G93A/mIgf-1 compared with SOD1
G93A
mice. (c) Western blot analysis of molecular
markers of muscle regeneration, activated sat-
ellite cells, and maturation. Muscle protein
lysates were obtained from quadriceps of wt
(lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A
(lanes 3 and 5) and SOD1
G93A/mIgf-1 (lanes
4 and 6) transgenic mice at different ages of
the clinical disease (lanes 3 and 4 at 28 d
old; lanes 5 and 6 at 123 d old). Immunoblot-
ting for  -tubulin served as a control for pro-
tein loading. (d) Immunofluorescence analysis
of MyHC-fast performed on soleus muscles of
wt, SOD1
G93A and SOD1
G93A/mIgf-1 before
(80 d) and after symptom onset (123, 138 d
old). Bar, 50  m. (e) Walk test of SOD1
G93A
(closed circles) and SOD1
G93A/mIgf-1 (open
circles) transgenic mice. 
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(not depicted). The alteration in the heterogeneity of SOD1
 
G93A
 
muscle fibers indicate an alteration in motor neuron activity
even before overt disease and support the hypothesis that de-
laying the progression and severity of ALS disease may depend
on the maintenance of muscle integrity.
The walk test analysis (Fig. 2 e), performed at different
ages, revealed that at 112 d SOD1
 
G93A
 
 mice (
 
n
 
 
 
 
 
 7) showed
symptom onset without evident alterations in functional param-
eters. The condition of SOD1
 
G93A
 
 mice rapidly deteriorated at
117 d, as shown by the shortening of their walk (Fig. 2 e). In
contrast, the pathological sign of disease were delayed in
SOD1
 
G93A
 
/mIgf-1 transgenic mice (
 
n   7), as shown by the ca-
pacity of the mice to walk 233   5.6 cm further when analyzed
at same age as SOD1
G93A mice, and by their ability to move for
a more extended period of time (Fig. 2 e).
These data suggest that promotion of muscle satellite cell
activity and hypertrophy through mIgf-1 can be considered as
an alternate therapeutic approach to counteract muscle wasting
associated with ALS disease.
An activated calcineurin isoform is 
induced in SOD1
G93A/mIgf-1 muscle
One of the signal transduction pathway involved in muscle
remodeling is the protein phosphatase calcineurin-A (CnA).
CnA overexpression has been implicated in myocyte hyper-
trophy (Musarò et al., 1999), fiber type conversion (Chin et
al., 1998), and tissue remodeling after injury (Sakuma et al.,
2003). In a study of selective CnA subunit isoform expres-
sion, we recently established that the alternatively spliced
variant CnA- 1 is up-regulated in regenerating skeletal
muscle fibers (unpublished data).
In this study, we verified whether activation of satellite
cells and maintenance of muscle phenotype involved the induc-
tion of CnA- 1 expression. Although the normally low levels
of CnA- 1 expression were not raised in SOD1
G93A muscles
(Fig. 3 a lane 3; Fig. 3 b lane 5, Fig. 3 c), or in uninjured wild-
type and MLC/mIgf-1 muscle (Fig. 3, a and b, lanes 1 and 2),
SOD1
G93A/mIgf-1 regenerating muscle dramatically increased
CnA- 1 transcripts (73   1.3%; Fig. 3 a lane 4) and protein
(52   2%; Fig. 3 b lane 6, Fig. 3 c) after onset of clinical symp-
toms. Thus, specific signaling elicited by CnA- 1 may contribute
to the prolongation of muscle integrity even after denervation.
Preservation of neuromuscular junctions 
in SOD1
G93A/mIgf-1 mice
Alterations in motor neuronal activity typical of denervated
muscle and motor neuron diseases also affect the configuration
of neuromuscular junctions in SOD1
G93A mice, characterized
by the diffusion of acetylcholine receptor (AChR) postsynap-
tic clusters (Fig. 4 a, yellow arrow). At 123 d, SOD1
G93A para-
lyzed muscle showed 56   0.2% of diffuse AChR expres-
sion, whereas AChR cluster aggregates (Fig. 4 a) were preserved
in muscles of age-matched SOD1
G93A/mIgf-1 mice, which
showed only 3.3   0.4% of diffuse AChR expression. At com-
parable end-stage disease, SOD1
G93A/mIgf-1 muscle displayed
only 18   0.4% of diffuse AChR expression. These results
were confirmed by Northern blot analysis (Fig. 4 b); high
AChR expression levels in SOD1
G93A muscle were reduced in
SOD1
G93A/mIgf-1 mice at all stages observed. Densitometric
analysis (n     6) revealed that AChR mRNA expression in
SOD1
G93A paralyzed muscle (123 d) was 68   2.4% higher
than that observed in age matched SOD1
G93A/mIgf-1 mice;
whereas the increase in mRNA expression in SOD1
G93A mice
was of 32   1.9% when SOD1
G93A and SOD1
G93A/mIgf-1 mice
where analyzed at comparable end-stage disease. This suggests
that mIgf-1 delays the progression of the disease, stabilizing
the innervation of muscle fibers.
The localization of AChR clusters at the end plate re-
quires the expression of agrin, a large proteoglycan in the syn-
aptic cleft that plays an important role in the maintenance of
the molecular architecture of the postsynaptic membrane (Mc-
Conville and Vincent, 2002). Agrin expression was signifi-
cantly down-regulated in paralyzed SOD1
G93A compared with
SOD
G93A/mIgf-1 muscle (Fig. 4 c) analyzed at comparable end-
Figure 3.  Transgenic mIgf-1 expression induces chronic CnA- 1 expression
in SOD1
G93A mice. (a) Northern blot analysis of CnA- 1 expression in wt
(lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A (lane 3) and SOD1
G93A/mIgf-1
(lane 4) transgenic mice. Ethidium bromide staining was used to verify
equal loading of the RNA sample. (b) Lysates of the same muscle tissues
used in Fig. 2 c were tested by Western blotting using a CnA- 1–specific
antibody. (c) Immunofluorescence of transverse sections from quadriceps
muscles of SOD1
G93A and SOD
G93A/mIgf-1 at paralysis stage. CnA- 1
shows a nuclear localization. A regenerating fiber is indicated by the
presence of central nucleus (red arrows). Nuclei were visualized by
Hoechst dye (blue). Bar, 20  m.MIGF-1 PROTECTS MOTOR NEURONS • DOBROWOLNY ET AL. 197
stage disease, further underscoring a role for local expression
of mIgf-1 in the maintenance of muscle innervation.
Muscle-restricted mIgf-1 prolongs motor 
neuronal function in SOD1
G93A mice
Histological analysis of the ventral spinal cord revealed that
SOD1
G93A mice (n   7) presented a progressive reduction in
the number of motor neuron from clinical onset to end-stage
disease. Specifically, SOD1
G93A mice showed a reduction of 37
and 55% in the number of motor neurons at clinical onset (112 d)
and at end-stage disease (123 d), respectively (Fig. 5 a). In
contrast, mIgf-1 expression induced motor neuron survival in
SOD1
G93A/mIgf-1 mice (n   7) at all ages and stages observed,
with significant differences at 112 and 123 d old (Fig. 5 a),
demonstrating that mIgf-1 expression preserves the motor neu-
ron during the progression of ALS.
One of the prominent markers of motor neuron dysfunc-
tion in ALS mice is the activation of astrocytes, leading to mo-
tor weakness and neural loss (Hall et al., 1998). Comparable
patterns of glial fibrillary acidic protein (GFAP) immunoreac-
tivity were found in spinal cords of SOD1
G93A (n   6) and
SOD
G93A/mIgf-1 (n   6) transgenic mice before the symptom
onset (28 d; Fig. 5 b, A, B, and D, insert, lanes 1 and 2). How-
ever, at paralysis stage (123 d) the spinal cord of SOD1
G93A
mice demonstrated a marked increase in astroglial activation
(Fig. 5 b C), with an increase in GFAP expression of  55  
0.2% (Fig. 5 b, D, insert, lane 3) compared with the GFAP ex-
pression levels displayed in the spinal cord of age matched
SOD1
G93A/mIgf-1 transgenic mice (Fig. 5 b, D and insert, lane
4). At comparable end-stage disease, there were no signifi-
cant differences in GFAP expression between SOD1
G93A and
SOD1
G93A/mIgf-1 mice, although SOD1
G93A mice continued to
express 13% more GFAP as compared with SOD1
G93A/mIgf-1
mice (unpublished data).
The activation of astroglia can be correlated with the ex-
pression of certain cytokines, such as TNF- , which enhance
Figure 4.  Maintenance of the neuromuscular junction configuration
in SOD1
G93A/mIgf-1 transgenic mice. (a) Immunofluorescent analysis of
transverse sections from muscles of wt, MLC/mIgf-1, SOD1
G93A and
SOD1
G93A/mIgf-1 transgenic mice at 123 d old.  -bungarotoxin antibody
identified diffusion of AChR expression in SOD1
G93A muscle (yellow ar-
row); whereas SOD
G93A/mIgf-1 muscle maintained AChR clusters. Bar, 20
 m. (b) Northern blot of total RNA samples from quadriceps of wt (lane 1),
MLC/mIgf-1 (lane 2), SOD1
G93A (lane 3) and SOD1
G93A/mIgf-1 (lanes 4
and 5) transgenic muscles at 123 (lanes 1–4) and 150 (lane 5) days old,
hybridized with AChR 
32P-labeled probe. Ethidium bromide staining was
used to verify equal loading of the RNA sample. (c) Western blot of agrin
from quadriceps of wt (lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A (lane
3) and SOD1
G93A/mIgf-1 (lane 4) transgenic muscles. SOD1
G93A and
SOD1
G93A/mIgf-1 mice were analyzed at comparable end-stage disease.
Figure 5.  Transgenic mIgf-1 expression protects motor neuron from
degeneration. (a) Quantification of surviving motor neurons in the ventral
spinal cord of wild-type, SOD1
G93A and SOD1
G93A/mIgf-1 mice at different
ages. *P   0.001; **P   0.001. (b) Immunofluorescence analysis identify
GFAP positive astrocytes in ventral horn of SOD1
G93A and SOD1
G93A/mIgf-1
mice at different ages: A and B, 28 d old; C and D, 123 d old. The inten-
sity of the GFAP signal revealed progressive astrocytosis. Bar, 20  m.
Insert in D shows Western blot for GFAP in the spinal cord of SOD1
G93A
(lanes 1 and 3) and SOD1
G93A/mIgf-1 (lanes 2 and 4) mice at 28 (lanes 1
and 2) and 123 (lanes 3 and 4) d old. (c) RT-PCR analysis of TNF-  and
 -actin of wt (lane 1), MLC/mIgf-1 (lane 2), SOD1
G93A (lane 3) and
SOD1
G93A/mIgf-1 (lane 4) transgenic mice at 123 d old. Lane 5 shows a
negative control (nc) consisting of RT-PCR mix without cDNA template. Lane 6
identifies the RNA positive control (pc) for TNF-  obtained from spleen.JCB • VOLUME 168 • NUMBER 2 • 2005 198
the response to inflammatory states and contribute to the pro-
gression of neurological dysfunction in SOD1
G93A mice (El-
liott, 2001). Although TNF-  expression was normally unde-
tectable in the CNS of healthy mice (Fig. 5 c, lanes 1 and 2), it
accumulated in the spinal cord of SOD1
G93A mice at paralysis
stage (123 d; Fig. 5 c, lane 3). In contrast, TNF-  expression
was not apparent in the spinal cord of SOD1
G93A/mIgf-1 trans-
genic mice (Fig. 5 c, lane 4). mIgf-1 hypertrophic muscle there-
fore functions as a protective tissue for the CNS, modulating
reactive astrocytosis and inflammatory cytokines that normally
exacerbate the pathogenesis of ALS disease.
ALS is emerging as a “multi-systemic” disease in which
the alteration in structural, physiological, and metabolic pa-
rameters in different cell types (muscle, motor neuron, glia)
may act synergistically to exacerbate the disease and evi-
dences a functional cross-talk between neuronal and not neu-
ronal cells (Rothstein et al., 1996; Ferri et al., 2004). The
present study serves to refocus therapeutic strategies to atten-
uate motor neuronal degradation toward skeletal muscle. It
remains to be determined whether the dramatic prolongation
of CNS tissue integrity in SOD1
G93A/mIgf-1 mice derives
from the direct retrograde transport of transgenic mIgf-1, or
indirect action either through distal activation of endogenous
Igf-1 expression, or through other trophic factors secreted by
SOD
G93A/mIgf-1 muscle.
In a previous study, retrograde transport of the AAV–Igf-1
vector from muscle to motor neuron was deemed necessary to
achieve the therapeutic effects, because the same gene deliv-
ered to the muscle by a lentiviral vector, which cannot ret-
rotransport, proved ineffective.
The results of the present study suggest other explana-
tions. The Igf-1 cDNA used by Kaspar et al. (2003) may have
encoded the more prevalent circulating gene product, which
once secreted from the muscle disperses in the circulation
(Musarò and Rosenthal, 2002). In contrast, the mIgf-1 iso-
form used in our present and previous studies (Barton-Davis
et al., 1998; Musarò et al., 2001; Barton et al., 2002; Musarò
et al., 2004) does not enter the circulation, but accumulates in
the tissue of synthesis where its autocrine/paracrine func-
tion is concentrated. The importance of Igf-1 isoform choice
in designing therapeutic strategies cannot be overstressed,
because their diverse biological activities lead to radically
different outcomes (for review see Musarò and Rosenthal,
2002). Whatever its mode of action, the feasibility of local-
ized synthesis of the mIgf-1 isoform to activate survival
mechanisms in distal damaged tissues represents a powerful
approach to counteract the degeneration of both muscle and
motor neuron in ALS disease.
Materials and methods
Mice
SOD
G93A transgenic mice (Jackson Laboratory) express a transgenic hu-
man mutant SOD1
G93A allele containing the Gly93 →Ala (G93A) substitu-
tion, driven by its endogenous human promoter (Gurney et al., 1994). The
SOD1
G93A B6J mice were crossed with MLC/mIgf-1 FVB mice (Musarò et
al., 2001) for seven different generations to obtain SOD1
G93A/mIgf-1 B6J
inbred transgenic mice.
Walk test
The walk test was performed in a scaled ramp, accordingly to the method
reported by Gurney et al. (1994). The mice were allowed to explore the
cage for 1 min and then they were left to walk for 2 min. The hind feet of
the mice were painted with ink and the track left by the mice were re-
corded on a paper tape. The test was performed in horizontal, laminar
flow hood to maintain barrier conditions.
Histological and immunofluorescence analysis
For histological analysis, 7- m tissue cryosections were fixed in 4% PFA
and stained with hematoxylin/eosin. For immunofluorescence analysis,
sections were fixed with 4% PFA, washed in PBS with 1% BSA and 0.2%
Triton X-100, preincubated for 1 h in 10% goat serum at RT, and incu-
bated overnight at 4 C with primary antibodies: neonatal MyHC (neo-
MyHC), MyHC-fast, Alexa Fluor 488–conjugated  -bungarotoxin, CnA- 1
(from C. Klee, National Institutes of Health, Bethesda, MD), GFAP. Nuclei
were visualized by Hoechst staining.
For motor neuron quantification, fixed spinal cord slices were 
immunostained with SMI-32 monoclonal antibody
Inverted microscope (Axioskop 2 plus; Carl Zeiss MicroImaging, Inc.)
using 20 or 40  lenses was used, and images were processed using
Axiovision 3.1.
RNA preparation and Northern analysis
RNA was extracted from muscles by RNA-TRIzol–kit (GIBCO BRL). Total
RNA was separated in 1.3% agarose gel and hybridized as described
previously (Musarò and Rosenthal, 1999).
RT-PCR analysis
RNA was isolated from spinal cord of wild-type, MLC/mIgf-1, and
SOD
G93A and SOD1
G93A/mIgf-1 transgenic mice. The following oligonu-
cleotides were used: TNF-  sense, 5 -CCCAGACCCTCACACACTCA-
GAT-3  and anti-sense, 5 -TTGTCCCTTGAAGAGAACCTG-3 ;   -actin
sense, 5 -GTGGGCCGCTCTAGGCACAA-3  and anti-sense, 5 -CTC-
TTTGATGTCACGCACGATTTC-3 .
Protein extraction and Western blot analysis
Protein extraction was performed in lysis buffer (50 mM Tris-HCl, pH 7.4,
1% wt/vol Triton X-100, 0.25% sodium deoxycholate, 150 mM sodium
chloride, 1 mM PMSF, 1  g/ml of each aprotinin, leupeptin, pepstatin, 1
mM sodium orthovanadate, 1 mM sodium fluoride). Equal amounts of pro-
tein from each muscle lysate were separated in SDS polyacrylamide gel
and transferred onto a hybond C extra nitrocellulose membrane. Filters
were blotted with antibodies against hSOD, Pax7, myogenin, desmin,
neo-MyHC (from S. Schiaffino, University of Padova, Padova, Italy), Ag-
rin, GFAP.
Online supplemental material
Organization of the Igf-1 gene. As its name implies, Igf-1 is similar to insu-
lin in structure. The mature Igf-1 is a single-chain protein of 70 aa and dif-
fers from insulin by retention of the C-domain, by a short extension of the
A-domain to include a novel domain D, and by the presence of variable
COOH-terminal extension peptides (E-peptides; Fig. S1). The rodent Igf-1
gene contains six exons, separated by five introns (Fig. S1). Exons 1 and
2 encode distinct 5 UTRs, as well as different parts of the signal peptide,
and are therefore termed leader exons. Separate promoters drive exons 1
and 2 transcription. Exon 3 encodes 27 aa that are part of the signal pep-
tide and common to all isoforms, as well as part of the mature Igf-1 pep-
tide. Exon 4 encodes the rest of the mature peptide and 16 aa of the NH2-
terminal region of the E-peptide, which is also common to all Igf-1 mRNAs.
Exons 5 and 6 encode two distinct COOH-terminal E-peptides (Ea, Eb)
and the 3 UTR. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200407021/DC1.
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